Td Waterhouse Canada Inc. Bei Gene, Ltd. Transaction History

Td Waterhouse Canada Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$143.93 - $224.51 $719 - $1,122	-5 Closed	0 $0
Q2 2024 Nov 12, 2024	BUY	$129.52 - $174.32 $647 - $871	5 New	5 $724,000
Q2 2023 Nov 13, 2023	SELL	$178.3 - $266.78 $3,922 - $5,869	-22 Closed	0 $0
Q1 2023 Nov 13, 2023	BUY	$215.53 - $274.5 $4,741 - $6,039	22 New	22 $4.68 Million
Q4 2022 Nov 13, 2023	SELL	$125.51 - $229.3 $1,004 - $1,834	-8 Closed	0 $0
Q2 2022 Nov 13, 2023	BUY	$121.11 - $216.05 $363 - $648	3 Added 60.0%	8 $1.48 Million
Q1 2022 Nov 13, 2023	BUY	$146.52 - $269.56 $439 - $808	3 Added 150.0%	5 $984,000
Q4 2021 Nov 13, 2023	BUY	$248.56 - $389.34 $497 - $778	2 New	2 $492,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Td Waterhouse Canada Inc., based on Form 13F filings with the SEC.

Stay updated on Td Waterhouse Canada Inc. with notifications on news.